Sylvain Garciaz

1.2k total citations
46 papers, 324 citations indexed

About

Sylvain Garciaz is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Sylvain Garciaz has authored 46 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 15 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Sylvain Garciaz's work include Acute Myeloid Leukemia Research (22 papers), Lymphoma Diagnosis and Treatment (11 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Sylvain Garciaz is often cited by papers focused on Acute Myeloid Leukemia Research (22 papers), Lymphoma Diagnosis and Treatment (11 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Sylvain Garciaz collaborates with scholars based in France, United States and Australia. Sylvain Garciaz's co-authors include Norbert Vey, Diane Coso, Réda Bouabdallah, Yves Collette, Yosr Hicheri, Colombe Saillard, Jean‐Marc Schiano de Colella, Didier Blaise, Bruno Chetaille and Sabine Fürst and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sylvain Garciaz

42 papers receiving 321 citations

Peers

Countries citing papers authored by Sylvain Garciaz

Since Specialization

Citations

This map shows the geographic impact of Sylvain Garciaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvain Garciaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvain Garciaz more than expected).

Fields of papers citing papers by Sylvain Garciaz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvain Garciaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvain Garciaz. The network helps show where Sylvain Garciaz may publish in the future.

Co-authorship network of co-authors of Sylvain Garciaz

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvain Garciaz. A scholar is included among the top collaborators of Sylvain Garciaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvain Garciaz. Sylvain Garciaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction 2025 ·Blood ·Sylvain Garciaz, (unknown), Pierre Péterlin, Daniel Morillo, José Miguel Torregrosa Diaz, Matthew L. Ulrickson, (unknown), Aude De Gassart, (unknown), Maelle Mairesse, George Saad, (unknown), Katrien Lemmens, (unknown), D Olive, Stephan Braun, Naval Daver, Abhishek Maiti	0
2	Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study 2024 ·Blood ·(unknown), Sarah Bertoli, (unknown), Maël Heiblig, Thibaut Leguay, Suzanne Tavitian, Éric Delabesse, (unknown), Emmanuelle Tavernier, Martin Carré, (unknown), Anne Banos, Norbert Vey, (unknown), Christian Récher, Sylvain Garciaz	0
3	A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia. 2024 ·Journal of Clinical Oncology ·Naval Daver, Pau Montesinos, Jessica K. Altman, Anjali S. Advani, Eunice S. Wang, Sylvain Garciaz, Giovanni Martinelli, Gail J. Roboz, Roland B. Walter, Kebede H. Begna, Monia Lunghi, Uwe Platzbecker, Paresh Vyas, Patrick W. Burke, Antonio Curti, Daniel J. DeAngelo, Lauris Gastaud, Christoph Schliemann, Benjamin Oshrine, David A. Sallman	1
4	Venetoclax Resistance in Acute Myeloid Leukemia 2024 ·Cancers ·Sylvain Garciaz, Yves Collette, Norbert Vey	16
5	Caspase-2 protects against ferroptotic cell death 2024 ·Cell Death and Disease ·Swati Dawar, (unknown), Yoon Lim, Toby A. Dite, Jumana M. Yousef, Niko Thio, Sylvain Garciaz, Thomas D. Jackson, (unknown), Laura F. Dagley, Wayne A. Phillips, Sharad Kumar, Nicholas J. Clemons	12
6	ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction 2024 ·Blood ·Abhishek Maiti, (unknown), Pierre Péterlin, Daniel Morillo, José Miguel Torregrosa Diaz, Paul Koller, Maelle Mairesse, (unknown), (unknown), Aude De Gassart, Katrien Lemmens, Daniel Olive, Naval Daver, Stephan Braun, Sylvain Garciaz	1
7	Erythroleukemia: Classification 2023 ·SHILAP Revista de lepidopterología ·Nathalie Cervera, Arnaud Guillé, José Adélaı̈de, Sylvain Garciaz, Julien Mozziconacci, Norbert Vey, Véronique Gelsi‐Boyer, Daniel Birnbaum	6
8	FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile 2023 ·OncoTargets and Therapy ·Sylvain Garciaz, (unknown)	13
9	Downregulation of stromal syntenin sustains AML development 2023 ·EMBO Molecular Medicine ·Raphaël Leblanc, Rania Ghossoub, Armelle Goubard, Rémy Castellano, Joanna Fares, Luc Camoin, Stéphane Audebert, (unknown), (unknown), Cyril Fauriat, Norbert Vey, Sylvain Garciaz, Jean‐Paul Borg, Yves Collette, Michel Aurrand‐Lions, Guido David, Pascale Zimmermann	6
10	Preliminary results of a phase 1, first-in-human study of INA03, an anti-CD71 antibody-drug conjugate, in patients with relapsed or refractory (R/R) acute leukemias. 2023 ·Journal of Clinical Oncology ·Sylvain Garciaz, Pierre Bories, (unknown), Jean‐Marie Boher, Coralie Bélanger, Christian Récher, Olivier Hermine, Norbert Vey, Pierre Launay	3
11	822O Activation of γ9δ2 T cells by ICT01 as a novel immunotherapeutic approach for relapsed/refractory hematologic cancers (EVICTION trial) 2023 ·Annals of Oncology ·Sylvain Garciaz, Stéphane Champiat, Pierre Péterlin, Katrien Lemmens, (unknown), (unknown), Emmanuel Di Valentin, (unknown), (unknown), Daniel Olive, Norbert Vey, Paul Frohna	2
12	Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study 2023 ·Blood ·Sylvain Garciaz, Sarah Bertoli, David A. Sallman, Justine Decroocq, Pierre‐Yves Dumas, Amine Belhabri, Corentin Orvain, (unknown), Célestine Simand, Kamel Laribi, Martin Carré, Alberto Santagostino, (unknown), (unknown), Arnaud Pigneux, Norbert Vey, Christian Récher	7
13	Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome 2023 ·Bone Marrow Transplantation ·Samia Harbi, (unknown), (unknown), Sylvain Garciaz, Thomas Pagliardini, Boris Calmels, (unknown), (unknown), Yosr Hicheri, Sabine Fürst, Claude Lemarié, (unknown), Faézeh Legrand, (unknown), Pierre Jean Weiller, Christian Chabannon, Norbert Vey, Didier Blaise, Raynier Devillier	8
14	Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study 2022 ·Bone Marrow Transplantation ·(unknown), Thomas Hueso, Thomas Gastinne, Catherine Thiéblemont, Lucie Obéric, Krimo Bouabdallah, Sylvain Garciaz, Emmanuelle Tchernonog, Caroline Dartigeas, Vincent Ribrag, Patrick Fogarty, Olivier Casasnovas, Roch Houot, (unknown), Sandra Malak, Luc‐Matthieu Fornecker, Rémy Gressin, Gandhi Damaj, Steven Le Gouill	3
15	Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients 2022 ·Cancers ·Sylvain Garciaz, (unknown), Colombe Saillard, Yosr Hicheri, Bilal Mohty, Jérôme Rey, Evelyne D’Incan, (unknown), (unknown), Valério Maisano, Laura Lombardi, (unknown), Julien Mozziconacci, Véronique Gelsi‐Boyer, Norbert Vey	36
16	Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO) 2022 ·Blood ·Sylvain Garciaz, Justine Decroocq, Sarah Bertoli, Amine Belhabri, Pierre‐Yves Dumas, Célestine Simand, Kamel Laribi, Alberto Santagostino, Martin Carré, Aline Schmidt, (unknown), Chantal Himberlin, Christian Récher, Norbert Vey	2
17	Analysis of a large single institution cohort of related donors fails to detect a relation between SDF1/CXCR4 or VCAM/VLA4 genetic polymorphisms and the level of hematopoietic progenitor cell mobilization in response to G-CSF 2020 ·PLoS ONE ·Sylvain Garciaz, (unknown), Angéla Granata, (unknown), (unknown), Boris Calmels, Claude Lemarié, Jacques Chiaroni, Didier Blaise, Jean‐Marie Boher, Christophe Picard, Christian Chabannon, Julie Di Cristofaro	4
18	Lymphomes hodgkiniens et non hodgkiniens des adolescents et des jeunes adultes 2016 ·Bulletin du Cancer ·Sylvain Garciaz, Diane Coso, Pauline Brice, Réda Bouabdallah	2
19	Patients’ Non-Medical Characteristics Contribute to Collective Medical Decision-Making at Multidisciplinary Oncological Team Meetings 2016 ·PLoS ONE ·(unknown), Thémis Apostolidis, Anne‐Déborah Bouhnik, Sylvain Garciaz, Thérèse Aurran, Claire Julian‐Reynier	20
20	Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients 2013 ·Leukemia & lymphoma ·Diane Coso, Sylvain Garciaz, Benjamin Esterni, Florence Broussais‐Guillaumot, (unknown), Thérèse Aurran‐Schleinitz, Jean‐Marc Schiano de Colella, Anne‐Marie Stoppa, Bruno Chetaille, Didier Blaise, Norbert Vey, Réda Bouabdallah	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact